Predicting the Restenosis Benefit of Drug-Eluting Versus Bare Metal Stents in Percutaneous Coronary Intervention | Zendy

Robert W. Yeh | Zendy; SharonLise T. Normand | Zendy; Robert Wolf | Zendy; Philip G. Jones | Zendy; Kalon K.L. Ho | Zendy; David J. Cohen | Zendy; Donald E. Cutlip | Zendy; Laura Mauri | Zendy; Aaron D. Kugelmass | Zendy; Amit P. Amin | Zendy; John A. Spertus | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Predicting the Restenosis Benefit of Drug-Eluting Versus Bare Metal Stents in Percutaneous Coronary Intervention

Author(s) -

Robert W. Yeh,

SharonLise T. Normand,

Robert Wolf,

Philip G. Jones,

Kalon K.L. Ho,

David J. Cohen,

Donald E. Cutlip,

Laura Mauri,

Aaron D. Kugelmass,

Amit P. Amin,

John A. Spertus

Publication year - 2011

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.111.045229

Subject(s) - medicine , restenosis , percutaneous coronary intervention , bare metal , cardiology , drug , coronary restenosis , drug eluting stent , percutaneous , stent , myocardial infarction , pharmacology

Drug-eluting stents (DES) for percutaneous coronary intervention decrease the risk of restenosis compared with bare metal stents. However, they are costlier, require prolonged dual antiplatelet therapy, and provide the most benefit in patients at highest risk for restenosis. To assist physicians in targeting DES use in patients at the highest risk for target vessel revascularization (TVR), we developed and validated a model to predict TVR.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research